Literature DB >> 17786032

MDA-MB-435: the questionable use of a melanoma cell line as a model for human breast cancer is ongoing.

Matthias Christgen1, Ulrich Lehmann.   

Abstract

In September 2006, Rae et al. provided unmistakable evidence that the MDA-MB-435 human breast cancer cell line is identical to the M14 human melanoma cell line. This discovery was no surprise to the breast cancer research community. In fact, the expression of melanocyte-specific marker proteins by MDA-MB-435 cells was first recognized many years ago. In 2007, the year after MDA-MB-435 cells were officially redefined as melanoma cells, this mix-up has gained a new aspect: We could easily identify 20 novel studies published in the recent issues of leading journals which simply proceeded to employ MDA-MB-435 cells as a model system for human breast cancer. Here we want to draw attention to this questionable practice which should further raise our (self-) skepticism and awareness about the true origin, the identity and molecular properties of any biological materials used in cancer research.

Entities:  

Mesh:

Year:  2007        PMID: 17786032     DOI: 10.4161/cbt.6.9.4624

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  21 in total

1.  Evaluation genotypes of cancer cell lines HCC1954 and SiHa by short tandem repeat (STR) analysis and DNA sequencing.

Authors:  Jiewen Fu; Jingliang Cheng; Xiaoyan Liu; Jun Li; Chunli Wei; Xiaoli Zheng; Tao He; Junjiang Fu
Journal:  Mol Biol Rep       Date:  2018-11-02       Impact factor: 2.316

2.  Chemotherapy targeting by DNA capture in viral protein particles.

Authors:  Hasmik Agadjanian; David Chu; Jae Youn Hwang; Sebastian Wachsmann-Hogiu; Altan Rentsendorj; Lei Song; Vinod Valluripalli; Jay Lubow; Jun Ma; Behrooz Sharifi; Daniel L Farkas; Lali K Medina-Kauwe
Journal:  Nanomedicine (Lond)       Date:  2012-03       Impact factor: 5.307

3.  2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion.

Authors:  Haibin Xi; Metin Kurtoglu; Huaping Liu; Medhi Wangpaichitr; Min You; Xiongfei Liu; Niramol Savaraj; Theodore J Lampidis
Journal:  Cancer Chemother Pharmacol       Date:  2010-07-01       Impact factor: 3.333

4.  Raf kinase inhibitor protein suppresses nuclear factor-κB-dependent cancer cell invasion through negative regulation of matrix metalloproteinase expression.

Authors:  Anwar B Beshir; Gang Ren; Anniefer N Magpusao; Lauren M Barone; Kam C Yeung; Gabriel Fenteany
Journal:  Cancer Lett       Date:  2010-09-19       Impact factor: 8.679

5.  Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using two-dimensional differential gel electrophoresis.

Authors:  Si-Guang Xu; Pei-Jun Yan; Zhi-Ming Shao
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-14       Impact factor: 4.553

6.  Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer.

Authors:  Brandon J Metge; Andra R Frost; Judy A King; Donna Lynn Dyess; Danny R Welch; Rajeev S Samant; Lalita A Shevde
Journal:  Clin Exp Metastasis       Date:  2008-06-20       Impact factor: 5.150

7.  Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.

Authors:  William Cruz-Munoz; Shan Man; Robert S Kerbel
Journal:  Clin Cancer Res       Date:  2009-07-21       Impact factor: 12.531

8.  Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth.

Authors:  Zhenwen Yan; Huafei Zou; Fang Tian; Jennifer R Grandis; A James Mixson; Patrick Y Lu; Lu-Yuan Li
Journal:  Mol Cancer Ther       Date:  2008-06-04       Impact factor: 6.261

Review 9.  Analysis of TP53 mutation status in human cancer cell lines: a reassessment.

Authors:  Bernard Leroy; Luc Girard; Antoinette Hollestelle; John D Minna; Adi F Gazdar; Thierry Soussi
Journal:  Hum Mutat       Date:  2014-05-06       Impact factor: 4.878

10.  Diet modulation is an effective complementary agent in preventing and treating breast cancer lung metastasis.

Authors:  Xiangmin Zhao; Gabriel Rezonzew; Dezhi Wang; Gene P Siegal; Robert W Hardy
Journal:  Clin Exp Metastasis       Date:  2014-05-15       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.